Patents by Inventor Hans Netter

Hans Netter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B INFECTION
    Publication number: 20240150412
    Abstract: Disclosed herein are compositions and methods for the treatment of hepatitis B infection, including chronic hepatitis B (CHB).
    Type: Application
    Filed: August 21, 2023
    Publication date: May 9, 2024
    Applicants: CLEARB THERAPEUTICS LTD., MELBOURNE HEALTH
    Inventors: Renae Walsh, Stephen Locarnini, Hans Netter, Ronald Farquhar
  • Methods and compositions for the treatment of hepatitis B infection
    Patent number: 11773141
    Abstract: Disclosed herein are compositions and methods for the treatment of hepatitis B infection, including chronic hepatitis B (CHB).
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: October 3, 2023
    Assignees: CLEARB THERAPEUTICS LTD., MELBOURNE HEALTH
    Inventors: Renae Walsh, Stephen Locarnini, Hans Netter, Ronald Farquhar
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B INFECTION
    Publication number: 20220002349
    Abstract: Disclosed herein are compositions and methods for the treatment of hepatitis B infection, including chronic hepatitis B (CHB).
    Type: Application
    Filed: May 9, 2019
    Publication date: January 6, 2022
    Inventors: Renae Walsh, Stephen Locarnini, Hans Netter, Ronald Farquhar
  • VACCINE DELIVERY SYSTEM
    Publication number: 20090220537
    Abstract: An isolated protein comprising a hepatitis B surface antigen (HBsAg) amino acid sequence, and encoding nucleic acid, are provided wherein one or more immunogenic T cell epitopes of the HBsAg are respectively substituted with one of more immunogenic T cell epitopes of a protein other than HBsAg. Typically, the T cell epitopes are of a pathogen or tumour protein. The isolated protein may have endogenous HBsAg epitopes substituted with multiple copies of the same epitope or with different HBsAg epitopes. B cell epitopes may also be present.
    Type: Application
    Filed: April 12, 2006
    Publication date: September 3, 2009
    Applicant: THE UNIVERSITY OF QUEENSLAND
    Inventors: Robert Tindle, Hans Netter, Wai Ping Yvonne Woo